Skip to main content

What are Advanced Filters?

A powerful set of filters to further drill into results and answer key questions about your target readers.

Templeton Support avatar
Written by Templeton Support
Updated over 2 years ago

Please note: These filters are only available to users with Plus and Premium packages.

Revenue

  • $0-$249MM

  • $250MM-$999MM

  • $1 Billion +

Capital Raised Past 3 Years (US$m)

  • If available

Development Stage

  • Discovery

  • IND/CTA Filed

  • Marketed

  • Phase 0

  • Phase I

  • Phase II

  • Phase III

  • Pre-Clinical

  • Pre-Registration

Highest Development Stage

  • Discovery

  • IND/CTA Filed

  • Marketed

  • Phase 0

  • Phase I

  • Phase II

  • Phase III

  • Pre-Clinical

  • Pre-Registration

Therapeutic Area

  • Cardiovascular

  • Central Nervous System

  • Dermatology

  • Ear Nose Throat Disorders

  • Gastrointestinal

  • Genetic Disorders

  • Genito Urinary System and Sex Hormones

  • Hematological Disorders

  • Hormonal Disorders

  • Immunology

  • Infectious Disease

  • Male Health

  • Metabolic Disorders

  • Mouth and Dental Disorders

  • Musculoskeletal Disorders

  • Non-Malignant Disorders

  • No Malignant Disorders

  • Nutritional Disorders

  • Oncology

  • Ophthalmology

  • Other Diseases

  • Respiratory

  • Toxicology

  • Undisclosed

  • Women's Health

Entity Type

  • Government

  • Independent

  • Institution

  • Joint Venture

  • Parent

  • Private

  • Public

  • Subsidiary

Drug Pipeline

  • Hyperlink to website (if available)

Drug Type

  • Biosimilar

  • Generic

  • Innovator

Application Type

  • ANDA-505(j)

  • BLA-351(a)

  • BLA-351(k)

  • NDA-505(b)(1)

  • NDA-505(b)(2)

Designation Type

  • Accelerated Approval

  • Accelerated Assessment

  • Breakthrough Therapy

  • Fast Track Designation

  • Innovative Licensing and Access Pathway (ILAP)

  • Orphan Drug Designation

  • PRIME Designation

  • Priority Review

  • Promising Innovative Medicine / Early Access to Medicines Scheme

  • Qualified Infectious Disease Product Designation (QIDP)

  • Rare Pediatric Disease Designation

  • Regenerative Medicine Advanced Therapy Designation (RMAT)

  • Sakigake Designation

Designation Status

  • Designated

  • Designated/ Approved

  • Designated/ Approved/ Withdrawn

  • Designated/ Withdrawn

Review Geography

  • China

  • EU

  • Japan

  • US

  • UK

Drug Descriptor

  • Adoptive Cell Therapy

  • ACT-Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T)

  • ACT-Cytotoxic T Lymphocyte Immunotherapy (CTL)

  • ACT-Natural Killer (NK) Cell Immunotherapy

  • ACT-T Cell Receptor (TCR) Immunotherapy

  • ACT-Tumor Infiltrating Lymphocyte Immunotherapy (TIL)

  • Allogenic Therapy

  • Antibiofilm Agents

  • Antiinfective Therapy

  • AT-Antibiotic Therapy

  • AT-Antifungal Therapy

  • Antiinflammatory Therapy

  • Artificial Intelligence (AI)

  • Autologous Therapy

  • Chemotherapy

  • DNA-Based

  • Genome Editing

  • GE-Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) System

  • GE-Homologous Recombination

  • GE-Transcription Activator Like Effector Nucleases (TALEN) System

  • GE-Zinc Finger Nuclease (ZFN) System

  • Immunomodulatory Therapy

  • Immuno-Oncology

  • IO-Cancer Vaccine

  • IO-Immune Checkpoint Modulator

  • IO-Immune Checkpoint Modulator-Immune Checkpoint Inhibitor

  • IO-Cancer Vaccine-Dendritic Cell Immunotherapy (DC Vaccine)

  • Microbiome Therapy

  • Multispecific Monoclonal Antibody

  • Non-Opiod Painkiller

  • Opiod Painkiller

  • Prophylactic Vaccine

  • Psychedelic Therapeutics

  • Radiopharmaceutical

  • Recombinant

  • Regenerative Medicine

  • RNA-Based

  • RNA-Based-mRNA-Based

  • Stem Cell Therapy

  • SCT-Hematopoietic Stem Cell Therapy

  • SCT-Non-Hematopoietic Stem Cell Therapy

  • SCT-Pluripotent Stem Cell Therapy

  • SCT-Pluripotent Stem Cell Therapy-Embryonic Stem Cell Therapy

  • SCT-Pluripotent Stem Cell Therapy-Induced Pluripotent Stem Cell (iPSC) Therapy

  • Steriod Therapy

  • Synthetic

  • Targeted Protein Degradation (TPD)

  • TPD-Deubiquitinating Enzyme Inhibitors

  • TPD-E1/E2/E3 Activators

  • TPD-Molecular Glue

  • TPD-Proteolysis Targeting Chimera (PROTAC)

  • TPD-Selective Androgen Receptor Degrader (SARD)

  • TPD-Selective Estrogen Receptor Degrader (SERD)

  • Targeted Therapy

  • Therapeutic Vaccine

Route of Administration

  • Enteral

  • Hemodialysis

  • Inhalation

  • Inj-Intravenous

  • Inj-Parenteral

  • Inj-Subcutaneous

  • Injection

  • Oral

  • Suppository

  • Top-Cutaneous

  • Top-Ophthalmic

  • Top-Transdermal

  • Topical

Molecule Type

  • Bio-Allergenic

  • Bio-Blood Derivative

  • Bio-Cell Therapy

  • Bio-GT-Antisense Gene Therapy

  • Bio-GT-RNAi Gene Therapy

  • Bio-Gene Therapy

  • Bio-Oncolytic Virus

  • Bio-Pep-Recombinant Peptide

  • Bio-Pep—Synthetic Peptide

  • Bio-Peptide

  • Bio-Polysaccharide

  • Bio-Pro-Ant-Monoclonal Antibody

  • Bio-Pro-Ant-Monoclonal Antibody Conjugated

  • Bio-Pro-Antibody

  • Bio-Pro-Enz-Recombinant Enzyme

  • Bio-Pro-Enzyme

  • Bio-Pro-Enz-Recombinant Enzyme

  • Bio-Pro-RP-Fusion Protein

  • Bio-Pro-Recombinant Protein

  • Bio-Pro-Synthetic Protein

  • Bio-Protein

  • Bio-Vac-DNA Vaccine

  • Bio-Vac-Inactivated Vaccine

  • Bio-Vac-Live Attenuated Vaccine

  • Bio-Vac-Recombinant Vector Vaccine

  • Bio-Vac-Subunit Vaccine

  • Bio-Vac-Toxoid Vaccine

  • Bio-Vac-mRNA-Vaccine

  • Bio-Vaccine

  • Biologic

  • Oligo-Antisense Oligonucleotide

  • Oligo-Antisense RNAi Oligonucleotide

  • Oligo-Aptamer

  • Oligonucleotide

  • Polymer

  • Small Molecule

Gene Therapy Vector

  • Non-Viral Vector

  • NonVV-Bacterial Vector

  • NonVV-Nanoparticle

  • NonVV-Plasmid

  • NonVV-Plas-Transposon

  • Viral Vector

  • VV-DNA Virus Vector

  • VV-DNA-Adeno Associated Virus (AAV)

  • VV-DNA-Adenovirus (AV)

  • VV-DNA-Herpes Simplex Virus (HSV)

  • VV-DNA-Poxvirus

  • VV-DNA-Pox-Vacciniavirus

  • VV-RNA Virus Vector

  • VV-RNA-Alphavirus

  • VV-RNA-Retrovirus

  • VV-RNA-Ret-Lentivirus

  • VV-RNA-Vesicular Stomatitis Virus (VSV)

Company Drug Count

  • If available

Expression Systems

  • Cell Culture

  • CC-Insect Cell Culture

  • CC-Insect Cell Culture-Sf9 Cells

  • CC-Mammalian Cell Culture

  • CC-Mammalian Cell Culture-Baby Hamster Kidney (BHK) Cells

  • CC-Mammalian Cell Culture-Chinese Hamster Ovary (CHO) Cells

  • CC-Mammalian Cell Culture-Human Embryonic Kidney (HEK) Cells

  • CC-Mammalian Cell Culture-Human Fibrosarcoma HT-1080 Cells

  • CC-Mammalian Cell Culture-Human PER.C6 Cells

  • CC-Mammalian Cell Culture-Mouse C127 Cells

  • CC-Mammalian Cell Culture-Mouse Myeloma NS0 Cells

  • CC-Mammalian Cell Culture-Mouse Myeloma Sp2/0 Cells

  • CC-Plant Cell Culture

  • Fermentation

  • Ferm-Bacterial Fermentation

  • Ferm-Bacterial Fermentation-Escherichia coli (E. coli)

  • Ferm-Bacterial Fermentation-Pseudomonas fluorescens (P. fluorescens)

  • Ferm-Yeast Fermentation

  • Ferm-Yeast Fermentation-Komagataella pastoris (K. pastoris)

  • Ferm-Yeast Fermentation-Pichia angusta (P. angusta)

  • Ferm-Yeast Fermentation-Saccharomyces cerevisiae (S. cerevisiae)

  • Transgenic Organism

  • TO-Transgenic Animal

Containment

  • Cytotoxic

  • High Potency Non-Cytotoxic

  • HPNC-Immunosppresants

  • HPNC-Kinase Inhibitors

  • HPNC-Nucleotide/Nucleoside

  • HPNC-Prostaglandins

  • HPNC-Retinoids

  • HPNC-Steriods

  • Requires Containment

  • RC-Cephalosporin

  • RC-Controlled Drugs

  • RC-Live Attenuated Vaccine

  • RC-Monobactams

  • RC-Penicillins

  • RC-Radiolabel

  • RC-Sex Hormones

Drug Release

  • Effervescent

  • Immediate Release

  • Modified Release

  • MR-Delayed Release

  • MR-Extended Release

  • Orally Dissolving

  • Osmotic Release

Controlled Substance

  • DEA Schedule

  • DEA Schedule-US-DEA Schedule II

  • DEA Schedule-US-DEA Schedule III

  • DEA Schedule-US-DEA Schedule IV

  • DEA Schedule-US-DEA Schedule V

Drug Formulation

  • Pegylation

  • Liposomal

Packaging

  • Ampoule

  • Blow-Fill-Seal

  • Cartridge

  • Cryopreserved Bag

  • Large Volume Parental (LVP)

  • LVP-LVP Bag

  • LVP-VLP Glass Bottle

  • Prefilled Device

  • PD-Auto-Injector

  • Prefilled Syringe (PFS)-Single Chamber

Solubility

  • Amorphous Solid Dispersion

  • ASD-Hot Melt Extrusion

  • ASD-Other

  • ASD-Spray Drying

  • Complexation Cyclodextrin Inclusion

  • Lipid-Based Delivery SEDDS/SMEDDS

  • Micronized/ Jet Milled

  • Nanoparticle/Nanocrystal/Nanodispersion

  • NNN-Nanoparticle/Crystal/Nanodispersion

API Source

  • In-house

  • Licensor/Partner

  • Outsourced

Dosage Source

  • In-house

  • Licensor/Partner

  • Outsourced

Packaging Source

  • In-house

  • Licensor/Partner

  • Outsourced


​

Did this answer your question?